190 related articles for article (PubMed ID: 25616823)
1. The THUNDER trial results: clearing the way or ushering the storm?
Jaff MR
JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt A):109-10. PubMed ID: 25616823
[No Abstract] [Full Text] [Related]
2. Percutaneous revascularization for peripheral arterial disease: paclitaxel saves the day.
Mahmud E
JACC Cardiovasc Interv; 2013 Mar; 6(3):290-2. PubMed ID: 23517841
[No Abstract] [Full Text] [Related]
3. Commentary: treatment of femoropopliteal in-stent restenosis for patients with diabetes: do we have an answer to the DEBATE?
Armstrong EJ; Laird JR
J Endovasc Ther; 2014 Feb; 21(1):9-11. PubMed ID: 24502478
[No Abstract] [Full Text] [Related]
4. Drug-coated balloons--the importance of packing and dosing antiproliferative drugs.
Hehrlein C
Catheter Cardiovasc Interv; 2015 Aug; 86(2):287-8. PubMed ID: 26198065
[TBL] [Abstract][Full Text] [Related]
5. Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial.
Tepe G; Schnorr B; Albrecht T; Brechtel K; Claussen CD; Scheller B; Speck U; Zeller T
JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt A):102-8. PubMed ID: 25616822
[TBL] [Abstract][Full Text] [Related]
6. Commentary: how do we deal with dissection after angioplasty?
Fanelli F; Cannavale A; Gazzetti M; D'Adamo A
J Endovasc Ther; 2013 Dec; 20(6):801-4. PubMed ID: 24325696
[No Abstract] [Full Text] [Related]
7. Commentary: comparative effectiveness of paclitaxel-based femoropopliteal interventions.
Armstrong EJ
J Endovasc Ther; 2014 Jun; 21(3):369-72. PubMed ID: 24915583
[No Abstract] [Full Text] [Related]
8. Commentary: aligning incentives of payer, facility, and provider: the lynchpin of providing more cost-effective care.
Sternbergh WC
J Endovasc Ther; 2013 Dec; 20(6):826-7. PubMed ID: 24325700
[No Abstract] [Full Text] [Related]
9. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.
Kinstner CM; Lammer J; Willfort-Ehringer A; Matzek W; Gschwandtner M; Javor D; Funovics M; Schoder M; Koppensteiner R; Loewe C; Ristl R; Wolf F
JACC Cardiovasc Interv; 2016 Jul; 9(13):1386-92. PubMed ID: 27388828
[TBL] [Abstract][Full Text] [Related]
10. David versus Goliath: the first round.
Micari A; Vadalà G
JACC Cardiovasc Interv; 2014 Sep; 7(9):1057-9. PubMed ID: 25234680
[No Abstract] [Full Text] [Related]
11. Missing the Forest for the Trees?: Drug-Eluting Balloon Treatment for Infrapopliteal Disease.
Tsai TT
JACC Cardiovasc Interv; 2015 Oct; 8(12):1623-5. PubMed ID: 26493254
[No Abstract] [Full Text] [Related]
12. Clinical Randomized Trial Evaluating Novel, Microcrystalline, and Biocompatible Polymer Paclitaxel-Coated Balloon for the Treatment of Femoropopliteal Occlusive Disease: The BIOPAC Trial.
Buszman PP; Nowakowski P; Milewski K; Orlik B; Żurakowski A; Ludyga T; Polczyk F; Dębiński M; Jelonek M; Kachel M; Gąsior M; Granada JF; Kiesz RS; Buszman PE
JACC Cardiovasc Interv; 2018 Dec; 11(23):2436-2438. PubMed ID: 30522679
[No Abstract] [Full Text] [Related]
13. The effectiveness of the paclitaxel-coated Luminor® balloon catheter versus an uncoated balloon catheter in superficial femoral and popliteal arteries in preventing vessel restenosis or reocclusion: study protocol for a randomized controlled trial.
Teichgräber U; Aschenbach R; Scheinert D; Zeller T; Brechtel K; Thieme M; Blessing E; Treitl M; Lichtenberg M; von Flotow P; Vogel B; Werk M; Riambau V; Wienke A; Lehmann T; Sixt S
Trials; 2016 Oct; 17(1):528. PubMed ID: 27793175
[TBL] [Abstract][Full Text] [Related]
14. Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain.
Zeller T; Brodmann M; Micari A; Keirse K; Peeters P; Tepe G; Scheinert D; Jaff MR; Rocha-Singh KJ; Li P; Schmahl R; Ansel GM;
Circ Cardiovasc Interv; 2019 Jan; 12(1):e007730. PubMed ID: 30630355
[No Abstract] [Full Text] [Related]
15. 1-Year Results of Paclitaxel-Coated Balloons for Long Femoropopliteal Artery Disease: Evidence From the SFA-Long Study.
Micari A; Vadalà G; Castriota F; Liso A; Grattoni C; Russo P; Marchese A; Pantaleo P; Roscitano G; Cesana BM; Cremonesi A
JACC Cardiovasc Interv; 2016 May; 9(9):950-6. PubMed ID: 27151609
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease.
Mehrotra S; Paramasivam G; Mishra S
Curr Cardiol Rep; 2017 Feb; 19(2):10. PubMed ID: 28185166
[TBL] [Abstract][Full Text] [Related]
17. How should I treat a restenosis after superficial femoral artery stenting?
Fusaro M; Cassese S; Byrne RA
EuroIntervention; 2013 Mar; 8(11):1342-5. PubMed ID: 23538161
[No Abstract] [Full Text] [Related]
18. In-stent restenosis management: the best is yet to come.
van den Berg JC
J Cardiovasc Surg (Torino); 2017 Aug; 58(4):508-517. PubMed ID: 28322039
[TBL] [Abstract][Full Text] [Related]
19. German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease.
Scheinert D; Schmidt A; Zeller T; Müller-Hülsbeck S; Sixt S; Schröder H; Weiss N; Ketelsen D; Ricke J; Steiner S; Rosenfield K
J Endovasc Ther; 2016 Jun; 23(3):409-16. PubMed ID: 27117972
[TBL] [Abstract][Full Text] [Related]
20. Angioplasty with drug coated balloons for the treatment of infrainguinal peripheral artery disease.
Werner M
Vasa; 2016 Sep; 45(5):365-72. PubMed ID: 27351416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
